Literature DB >> 25644564

[Association of microvascular invasion with recurrence and prognosis of patients with small hepatocellular carcinoma undergoing liver transplantation].

Yang-Bo Zhu1, Xiao Xu1, Shu-Sen Zheng1.   

Abstract

OBJECTIVE: To evaluate the risk factors for recurrence in patients with hepatocellular carcinoma (HCC) after liver transplantation (LT).
METHODS: One hundred and fifteen small HCC patients, who met Milan criteria (single<5 cm or showing up to three nodules, each of them<3 cm without major vascular invasion or distant metastasis) and underwent LT in our hospital from January 2007 to November 2013, were enrolled in the study. The risk factors for recurrence were analyzed by Cox regression and the influence of the Milan criteria and microvascular invasion (MVI) on the disease-free survival (DFS) and recurrence of patients were assessed with survival analysis and ROC method.
RESULTS: Ninety-eight out of 115 small HCC patients were included for analysis, the 1-,3-, 5-year overall survival of patients was 91.8%, 80.6%, 79.6% and DFS was 87.8%, 74.5%, 73.5%, respectively. Survival analysis identified that MVI, macro-vascular invasion, exceeding the Milan criteria and pre-transplant down-staging treatment were related to tumor recurrence (P<0.05). Multivariate Cox regression analysis showed that MVI and exceeding the Milan criteria were two independent prognostic indicators for early recurrence of small HCC after LT. The 1-,3-,5-year DFS for 69 patients without MVI and 29 patients with MVI were 92.8%, 85.5%, 85.5% and 75.9%, 55.2%, 48.3%, respectively (P<0.01). The 1-,3-,5-year DFS for 84 patients meeting the Milan criteria and 14 exceeding the Milan criteria were 91.7%, 83.3%, 79.8% and 64.3%, 42.9%, 42.9%, respectively (P<0.01).
CONCLUSION: For early HCC patients undergoing LT, the presence of MVI would predict tumor recurrence and can be an indicator for the adjuvant treatment or other salvage treatments.

Entities:  

Mesh:

Year:  2014        PMID: 25644564     DOI: 10.3785/j.issn.1008-9292.2014.11.004

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN: 1008-9292


  2 in total

1.  Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection.

Authors:  Chao He; Wei Peng; Chuan Li; Tian-Fu Wen
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

2.  Transcatheter arterial chemoembolization combined with simultaneous DynaCT-guided microwave ablation in the treatment of small hepatocellular carcinoma.

Authors:  Zhaonan Li; Dechao Jiao; Xinwei Han; Guangyan Si; Yahua Li; Juanfang Liu; Yanneng Xu; Bo Zheng; Xun Zhang
Journal:  Cancer Imaging       Date:  2020-01-30       Impact factor: 3.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.